GlassScriptPhysician profile
Daniel W Grisham
NPI 1073557575
$2,728.10
in general payments reported to CMS, 2019-2025
30 companies · $1,027 in 2025
The $1,027 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $275 · 2020: $119 · 2022: $112 · 2023: $632 · 2024: $563 · 2025: $1,027.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,221.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $462.28 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $341.81 | 2019-2025 | |
| Lilly USA, LLC | $335.64 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $192.16 | 2023-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $158.80 | 2019-2025 | Farxiga, Breztri |
| Dexcom, INC. | $149.63 | 2022-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $141.16 | 2019-2025 | |
| Abbott Laboratories | $97.81 | 2024-2025 | |
| Glaxosmithkline, LLC. | $97.38 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.51 | 2019-2023 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $74.47 | 2023-2025 | |
| Abiomed | $65.67 | 2024-2025 | Impella |
| Xeris Pharmaceuticals, INC. | $64.95 | 2023-2024 | Gvoke Hypopen |
| Amgen INC. | $57.53 | 2019-2025 | Repatha, Otezla, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $53.09 | 2023-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.68 | 2024-2025 | Xifaxan |
| Exact Sciences Corporation | $44.69 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boston Scientific Corporation | $38.72 | 2020-2025 | Watchman Flx |
| Phathom Pharmaceuticals, INC. | $27.83 | 2024 | Voquezna |
| Daiichi Sankyo INC. | $24.45 | 2022 | |
| Edwards Lifesciences Corporation | $22.51 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Lundbeck LLC | $20.37 | 2024 | Rexulti |
| Inspire Medical Systems, INC. | $19.70 | 2025 | Inspire |
| Astellas Pharma US INC | $19.36 | 2019 | |
| Medtronic, INC. | $18.40 | 2025 | Intellis Adaptivestim |
| Arbor Pharmaceuticals, INC. | $16.46 | 2019 | |
| Merck Sharp & Dohme LLC | $14.77 | 2025 | Capvaxive |
| Janssen Pharmaceuticals, INC | $14.65 | 2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $13.14 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Grisham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.